Celltrion to Participate in '2024 CPHI'... Actively Securing CDMO Partners

Celltrion announced on the 2nd that it will participate in the '2024 World Pharmaceutical & Bio Exhibition (CPHI)' held in Milan, Italy, for three days from the 8th to the 10th (local time).

A bird's-eye view of the Celltrion promotional booth set up at the '2024 World Pharmaceutical & Bio Exhibition (CPHI)' to be held in Milan, Italy, from the 8th to the 10th (local time) [Photo by Celltrion]

Celebrating its 35th anniversary this year, CPHI is the world's largest pharmaceutical and bio exhibition, attended annually by more than 60,000 experts from over 170 countries who promote their competitiveness and seek partnerships. Since 2022, Celltrion has been setting up a solo booth at the exhibition hall every year, focusing on brand promotion and strengthening partnering.

This year, Celltrion plans to install a large solo booth of approximately 165㎡ in the main aisle of the venue, including a dedicated meeting room and separate meeting spaces. The booth will host numerous partnering meetings and provide souvenirs through various events and surveys.

Celltrion is continuously expanding its pipeline with the addition of new products such as the newly launched drug Jimtentra, sold in the United States, and Stekima and Omriclo, which have obtained approval in Europe. Accordingly, recognizing the need to secure production and supply competitiveness to expand its global market share, Celltrion plans to intensify partnering efforts in related fields at this CPHI.

In particular, Celltrion aims to make every effort to secure new partners in overseas raw material suppliers, contract manufacturing organizations (CMO), and contract development and manufacturing organizations (CDMO) to strengthen product cost competitiveness. Additionally, it will explore potential partners possessing technologies in a wide range of business areas, including new formulation development, antibody-drug conjugates (ADC), antibody drugs, and chemicals, and engage in discussions for future joint development.

A Celltrion representative said, “We have made thorough preparations to attend CPHI again this year to showcase Celltrion’s portfolio, technological capabilities, and production capacity, and to identify promising partners. Celltrion, equipped with a stable supply chain and multi-product strategy, will do its utmost to seek partnerships with various global companies where synergy can be created.”